Novartis AG (SWX:NOVN)
97.88
+0.36 (0.37%)
Aug 14, 2025, 1:45 PM CET
Novartis AG Revenue
Novartis AG had revenue of $14.84B USD in the quarter ending June 30, 2025, with 15.26% growth. This brings the company's revenue in the last twelve months to $55.19B, up 12.95% year-over-year. In the year 2024, Novartis AG had annual revenue of $51.72B with 10.85% growth.
Revenue (ttm)
$55.19B
Revenue Growth
+12.95%
P/S Ratio
4.30
Revenue / Employee
$727.25K
Employees
75,883
Market Cap
188.78B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Lonza Group AG | 7.09B |
Alcon | 8.77B |
Galderma Group AG | 3.73B |
Sandoz Group AG | 8.42B |
Straumann Holding AG | 2.50B |
Sonova Holding AG | 3.87B |
Ypsomed Holding AG | 748.87M |
Novartis AG News
- 1 day ago - Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder - Benzinga
- 2 days ago - Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure - GlobeNewsWire
- 2 days ago - Roche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: Reuters - Seeking Alpha
- 2 days ago - Swiss government to meet pharma firms to discuss US tariffs - Reuters
- 2 days ago - Novartis succeeds in late-stage Sjögren's disease trials - Seeking Alpha
- 3 days ago - Rheinmetall, rsted, Novartis: Global Stocks in Focus - The Wall Street Journal
- 3 days ago - Novartis AG Announces Positive Phase III Trial Results for Ianalumab in Sjögren's Disease | ... - GuruFocus
- 3 days ago - Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients ... - GuruFocus